Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
REGN Revenue Growth (YoY Quarterly)•+2.51%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+2.51%
+1.6pp
+2.35%
+2.3pp
+9.67%
-8.2pp
-11.14%
+1.8pp
-7.97%
-16.9pp
-3.75%
-17.4pp
-2.48%
-20.5pp
-4.63%
-0.5pp
-5.54%
+2.2pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +10.33% | -3.70% | +3.62% | +0.90% | +2.51% |
| Gross Profit Growth | +14.92% | -5.41% | +2.56% | +0.10% | +2.35% |
| EBITDA Growth | -14.38% | +25.24% | -6.02% | +17.86% | +9.67% |
| Operating Income Growth | -5.76% | -21.25% | +0.93% | -12.95% | -11.14% |
| Net Income Growth | -20.86% | +12.01% | -2.84% | +8.91% | -7.97% |
| EPS Growth | -21.60% | +13.13% | -0.08% | +13.63% | -3.75% |
| EPS Diluted Growth | -20.90% | +15.95% | +3.22% | +18.02% | -2.48% |
| Weighted Average Shares Growth | +1.22% | -1.02% | -2.78% | -4.14% | -4.63% |
| Weighted Average Shares Diluted Growth | +0.00% | -3.39% | -5.89% | -7.75% | -5.54% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +15.89% | -30.90% | +223.28% | +25.36% | -7.29% |
| Free Cash Flow Growth | +28.29% | -42.73% | +576.17% | +27.96% | -7.41% |
| Receivables Growth | +9.61% | +6.49% | -1.87% | -6.88% | -7.58% |
| Inventory Growth | +19.64% | +17.59% | +11.55% | +7.83% | +3.68% |
| Asset Growth | +14.15% | +9.24% | +5.91% | +7.28% | +7.41% |
| Book Value per Share Growth | +11.65% | +10.00% | +9.17% | +10.13% | +11.66% |
| Debt Growth | +0.06% | +0.06% | +0.06% | +0.06% | +0.06% |
| R&D Expense Growth | +35.72% | +6.71% | +16.98% | +17.35% | +14.04% |
| SG&A Expenses Growth | +12.46% | -8.13% | -16.42% | -7.92% | -2.17% |
1 / 4